文献速递眼底病与葡萄膜炎

Faricimab每四个月和每季度给药对比雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效:STAIRWAY 2期随机临床试验

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项2期随机临床试验纳入76例新生血管性年龄相关性黄斑变性患者,比较faricimab每12周或16周给药与雷珠单抗每4周给药的疗效。第40周时,三组最佳矫正视力(BCVA)平均增益分别为+11.4、+9.3和+12.5个ETDRS字母,faricimab延长给药方案维持了与每月雷珠单抗相当的视力和解剖学改善。

要点

  • Faricimab每12周或16周给药在52周内维持了与每4周雷珠单抗相当的初始视力和解剖学改善。
  • 第24周时,65%(36/55)的faricimab治疗患者无疾病活动。
  • 未发现新的或非预期的安全性信号。

核心结论

  • 第52周时,faricimab每16周和每12周给药维持了与每月雷珠单抗相当的初始视力和解剖学改善。

研究设计与样本

  • 这项2期随机临床试验为52周多中心、阳性对照、平行组研究,2017年1月至3月在美国25个中心入组76例新生血管性年龄相关性黄斑变性患者。

主要发现

  • 第40周时,雷珠单抗每4周组、faricimab每12周组和faricimab每16周组校正后BCVA较基线平均增益分别为+11.4(80%CI 7.8-15.0)、+9.3(80%CI 6.4-12.3)和+12.5(80%CI 9.9-15.1)个ETDRS字母。
  • 第24周时,所有faricimab治疗患者中65%(36/55)无疾病活动。
  • 截至第52周,雷珠单抗每4周组、faricimab每12周组和faricimab每16周组平均(SD)总注射次数分别为12.9(0.25)、6.7(0.91)和6.2(0.93)次。
  • 次要BCVA和解剖学影像终点支持主要终点,且与每4周雷珠单抗相当。
  • 未发现新的或非预期的安全性信号。

关键数值与推荐

  • 入组患者为继发于新生血管性年龄相关性黄斑变性的初治脉络膜新生血管,BCVA ETDRS字母评分73(约Snellen 20/40)至24(约Snellen 20/320)。
  • 患者按1:2:2随机接受玻璃体腔内雷珠单抗0.5 mg每4周、或faricimab 6.0 mg每12周或每16周。
  • faricimab组初始接受4次每月注射,不允许救援注射;每16周组在第24周按预设标准评估疾病活动,无活动者继续每16周给药至试验结束,有活动者转为每12周给药。

临床怎么用

  • Faricimab每12周或每16周延长给药方案可在52周内维持与每月雷珠单抗相当的视力和解剖学改善,并显著减少注射次数。

局限性

  • 本研究为2期临床试验,样本量较小(76例),需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. OBJECTIVE: To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular degeneration. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial was a 52-week multicenter, active comparator-controlled, parallel-group study. Study participants were enrolled in 25 sites in the US from January and March 2017 with treatment-naive choroidal neovascularization secondary to neovascular age-related macular degeneration and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score of 73 (approximate Snellen equivalent, 20/40) to 24 (approximate Snellen equivalent, 20/320). Analysis began January 2017 and ended March 2018. INTERVENTIONS: Participants were randomized 1:2:2 to receive intravitreal ranibizumab, 0.5 mg, every 4 weeks or faricimab, 6.0 mg, every 12 or 16 weeks. Participants in the faricimab arms initially received 4 monthly injections of faricimab. No rescue injections were allowed. Participants randomized to dosing every 16 weeks were assessed for disease activity at week 24 using prespecified criteria. Those with no active disease continued dosing every 16 weeks through trial end; participants with disease activity continued received dosing every 12 weeks. MAIN OUTCOMES AND MEASURES: Mean change in BCVA from baseline at week 40. RESULTS: Of 76 participants enrolled (mean [SD] age, 78.5 [8.5] years; age range, 56-94 years; 41 women [58%]; 69 white [97%]), 16 (21.0%) were randomized to ranibizumab every 4 weeks, 29 (38.2%) to faricimab every 12 weeks, and 31 (40.8%) to faricimab every 16 weeks. At week 24, 12 weeks after their last initiation injection, 65% (36 of 55) of all faricimab-treated participants had no disease activity. At week 40, adjusted mean BCVA gains from baseline (Early Treatment Diabetic Retinopathy Study letters) were +11.4 (80% CI, 7.8-15.0), +9.3 (80% CI, 6.4-12.3), and +12.5 (80% CI, 9.9-15.1) for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively. Participants received a mean (SD) total of 12.9 (0.25), 6.7 (0.91), and 6.2 (0.93) injections, for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively, through week 52. The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks. No new or unexpected safety signals were identified. CONCLUSIONS AND RELEVANCE: At week 52, faricimab dosing every 16 weeks and every 12 weeks resulted in maintenance of initial vision and anatomic improvements comparable with monthly ranibizumab. These results suggest a role for simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A in providing sustained efficacy through extended durability, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03038880.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32729897. doi:10.1001/jamaophthalmol.2020.2699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。